Article Text

Download PDFPDF
Microsatellite instability diagnosis using the fully automated Idylla platform: feasibility study of an in-house rapid molecular testing ancillary to immunohistochemistry in pathology laboratories
  1. Laura Samaison1,
  2. Mélanie Grall1,
  3. Frédéric Staroz1,
  4. Arnaud Uguen2
  1. 1 Ouest Pathologie, Quimper, France
  2. 2 Pathology, CHRU Brest, Brest, France
  1. Correspondence to Dr Arnaud Uguen, Pathology, CHRU Brest, Brest 29200, France; arnaud.uguen{at}


Aim To study the performances of the Idylla MSI Assay in the diagnosis of microsatellite instability (MSI) or microsatellite stability (MSS).

Methods We selected 12 tumour samples previously tested for MSI focusing on cases with discrepant results between MLH1, PMS2, MSH2 and MSH6 immunohistochemistry and microsatellite molecular analyses (five cases) or doubtful immunohistochemistry (two cases). Idylla MSI Assay was compared with retrospective immunohistochemistry and molecular results.

Results Idylla MSI Assay showed an almost perfect concordance with microsatellite analysis results previously obtained (only one case with not fully conclusive analysis due to sample exhaustion). The full molecular analysis took less than 150 min per sample and revealed no mutation in any of the seven microsatellite sequences in five MSS samples and four to six mutated ones in seven MSI-High samples.

Conclusion At the era when the determination of MSI/MSS status is becoming important for rapid treatment choices, the Idylla MSI Assay consists of a valuable easy-to-perform diagnostic tool that allows, complementary to MLH1, PMS2, MSH2 and MSH6 immunohistochemistry, the diagnosis of MSI/MSS status in a single day.

  • microsatellite instability
  • mismatch repair deficiency
  • Idylla
  • immunohistochemistry
  • colorectal cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Runjan Chetty.

  • Contributors AU, LS and FS designed the study. LS and MG performed the molecular analyses. AU reviewed the immunohistochemistry analyses. AU, LS, FS and MG wrote and approved the final version of the manuscript.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Disclaimer Biocartis has provided Idylla dedicated cartridges for this study but has not taken part in data interpretation or manuscript writing in this work.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by institutional review board (CHRU Brest, CPP No DC-2008-214).

  • Provenance and peer review Not commissioned; externally peer reviewed.